VAN NOSTRAND ROBERT L — SEC Form 4 filings
SEC reporting owner CIK 1225198. 12 Form 4 filings on record with FilingPulse; latest filed 2026-01-09.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-01-25 to 2026-01-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 10,000 shares, $14,800 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 4 legs across 2 filings — 40,000 shares, $2,976,849 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 26.
- Largest priced transaction: sale of 11,109 shares @ $76.07 ($845,062) in Intra-Cellular Therapies, Inc., filed 2024-06-21.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Intra-Cellular Therapies, Inc. (ITCI) | Director | 7 | — | 4 legs · 40,000 sh · $2,976,849 | 20 |
| SELLAS Life Sciences Group, Inc. (SLS) | Director | 4 | 1 leg · 10,000 sh · $14,800 | — | 5 |
| YIELD10 BIOSCIENCE, INC. (YTEN) | Director | 1 | — | — | 1 |
Form 4 filings — VAN NOSTRAND ROBERT L
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-01-09 | 4 | SELLAS Life Sciences Group, Inc. (SLS) | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2025-06-13 | 4 | SELLAS Life Sciences Group, Inc. (SLS) | Purchase (P): 10,000 @ $1.48 | EDGAR |
| 2025-04-02 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Disposition to issuer (D): 11,340 @ $132 · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · +4 more | EDGAR |
| 2025-01-14 | 4 | SELLAS Life Sciences Group, Inc. (SLS) | Grant/award (A): 12,500 @ $0 · Grant/award (A): 18,500 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 83 @ $68.49 | EDGAR |
| 2024-06-25 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 1,567 · Option exercise (M): 1,567 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 20,000 @ $16.86 · Sale (S): 8,891 @ $75.71 · Sale (S): 11,109 @ $76.07 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 2,951 (derivative) @ $0 · Grant/award (A): 4,322 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Grant/award (A): 79 @ $69.20 | EDGAR |
| 2024-04-01 | 4 | YIELD10 BIOSCIENCE, INC. (YTEN) | Grant/award (A): 11,924 @ $0 | EDGAR |
| 2024-02-28 | 4 | Intra-Cellular Therapies, Inc. (ITCI) | Option exercise (M): 20,000 @ $18.56 · Sale (S): 9,651 @ $72.71 · Sale (S): 10,349 @ $73.14 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-01-25 | 4 | SELLAS Life Sciences Group, Inc. (SLS) | Grant/award (A): 6,000 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1225198 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →